Fig. 1: Consort diagram of the AML-12 protocol. | Blood Cancer Journal

Fig. 1: Consort diagram of the AML-12 protocol.

From: Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

Fig. 1

Each level represents a treatment cycle. Colors refer to ELN-22 risk category (blue: favorable, yellow: intermediate and red: adverse), and within them patients are distributed according to different genetic categories and age groups (n ≤ 60 | n > 60 years). Smaller squares between cycles show n of patients who discontinued protocol and their causes. CETLAM-fav includes ELN-22 favorable genetic categories plus NPM1mut/FLT3low. AlloHCT allogeneic stem cell transplant, CR1 first complete remission, CEBPAbi CEBPAbzip.

Back to article page